UNCY - NASDAQ

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.50

+4.7%

HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$161.19M

EPS-1.6700

P/E Ratio-4.49

Earnings Date08/13/2026

uncy

Total Stockholders' Equity

Last Annual Value

30.20M

3-Year CAGR

306%

5-Year CAGR

68%

10-Year CAGR

39%

Adjust for Inflation

Unicycive Therapeutics, Inc. Competitors Analysis of Total Stockholders' Equity

UNCY · NASDAQ

Company	Total Stockholders' Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Unicycive Therapeutics, Inc. NASDAQ:UNCY	30.20M	N/A	12.9%	N/A
Vaxart, Inc. NASDAQ:VXRT	87.80M	14.9%	-14.1%	16.7%
Cibus, Inc. NASDAQ:CBUS	21.83M	-57.9%	9.1%	5.2%
Fortress Biotech, Inc. NASDAQ:FBIO	49.87M	30.3%	-14.4%	2.6%
Nutriband Inc. NASDAQ:NTRB	6.43M	-0.0%	-11.5%	75.6%
ImageneBio Inc NASDAQ:IMA	133.14M	-7.8%	-8.5%	N/A
Shattuck Labs, Inc. NASDAQ:STTK	82.39M	-17.1%	-21.2%	N/A
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	104.71M	-22.6%	-19.4%	N/A
MindWalk Holdings Corp. NASDAQ:HYFT	23.63M	-25.8%	-16.1%	38.5%
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV	112.52M	-2.4%	N/A	N/A
Biomea Fusion, Inc. NASDAQ:BMEA	29.55M	-44.1%	-30.2%	N/A

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.5, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $7.5

Related Guides

Blog Categories

Continue your UNCY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.